Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation

Cytotherapy

Volumn 13, Issue 8, 2011, Pages 976-986

  Hanley, Patrick J ^a,b   Shaffer, Donald R ^b   Cruz, Conrad R Y ^c   Ku, Stephanie ^c   Tzou, Benjamin ^c   Liu, Hao ^b   Demmler Harrison, Gail ^b   Heslop, Helen E ^c   Rooney, Clio M ^b   Gottschalk, Stephen ^c   Bollard, Catherine M ^b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

adenovirus; adoptive immunotherapy; antiviral immunity; cytomegalovirus; cytotoxic T lymphocytes; EpsteinBarr virus; stem cell transplant

Indexed keywords

ADENOVIRUS ANTIGEN; ADENOVIRUS VECTOR; CYTOMEGALOVIRUS ANTIGEN IE 1; CYTOMEGALOVIRUS ANTIGEN PP65; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; GAMMA INTERFERON; PEPTIDE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADENOVIRUS; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; EPITOPE MAPPING; EPSTEIN BARR VIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; LYMPHOCYTE TRANSFORMATION; MEMORY T LYMPHOCYTE; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

EID: 80051907647     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.575356     Document Type: Article

References (43)

1. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O ' Gorman P, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99:4357-63. (Pubitemid 34627201)
2. Chakrabarti S, Mautner V, Osman H, Collingham KE, Fegan CD, Klapper PE, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 2002;100:1619-27. (Pubitemid 34925137)
3. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15: 1143-238.
4. Bao L, Dunham K, Stamer M, Mulieri KM, Lucas KG. Expansion of cytomegalovirus pp65 and IE-1 specifi c cytotoxic T lymphocytes for cytomegalovirus-specifi c immunotherapy following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:1156-62.
5. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev. 1999;12:286-97. (Pubitemid 29196854)
6. Mentzer SJ, Perrine SP, Faller DV. Epstein- Barr virus posttransplant lymphoproliferative disease and virus-specifi c therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl Infect Dis. 2001;3:177-85. (Pubitemid 32756700)
7. Lindemans CA, Leen AM, Boelens JJ. How I treat adenovirus in haematopoietic stem cell transplantation recipients. Blood. 2010;116:5476-85;
8. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, et al. Monoculture-derived T lymphocytes specifi c for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12:1160-6. (Pubitemid 44527351)
9. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodefi cient humans by the adoptive transfer of T cell clones. Science. 1992;257:238-41.
10. O' R eilly RJ, Doubrovina E, Trivedi D, Hasan A, Kollen W, Koehne G. Adoptive transfer of antigen-specifi c T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants. Immunol Res. 2007;38:237-50. (Pubitemid 47574910)
11. + virus-specifi c cytotoxic T lymphocytes. J Med Virol.1994;43:103-10. (Pubitemid 24146353)
12. Greenberg PD, Reusser P, Goodrich JM, Riddell SR. Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specifi c T cell clones expanded in vitro. Ann NY Acad Sci. 1991;636:184-95.
13. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virusspecifi c T-cell lines. Lancet. 2003;362:1375-7. (Pubitemid 37338339)
14. Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specifi c CD8 T cells. J Exp Med. 2005;201:1031-6. (Pubitemid 40524670)
15. Besold K, Frankenberg N, Pepperl-Klindworth S, Kuball J, Theobald M, Hahn G, et al. Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2-11-mediated immune evasion. J Gen Virol. 2007;88:1429-39. (Pubitemid 46723223)
16. Gilbert MJ, Riddell SR, Plachter B, Greenberg PD. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature. 1996;383: 720-2. (Pubitemid 26360648)
17. + T cells recognizing a broad repertoire ofcytomegalovirus pp65 and IE1 epitopes for highly specifi c adoptive immunotherapy. Cytotherapy. 2010;12:933-44.
18. Slezak SL, Bettinotti M, Selleri S, Adams S, Marincola FM, Stroncek DF CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. J Transl Med. 2007;5:17.
19. Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, et al. Antigen-specifi c T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. J Clin Virol. 2006;35:332-7. (Pubitemid 43188984)
20. Micklethwaite KP, Savoldo B, Hanley PJ, Leen AM, Demmler- Harrison GJ, Cooper LJ, et al. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specifi city from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010;115:2695-703.
21. Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009;114:4283-92.
22. Sili U, Huls MH, Davis AR, Gottschalk S, Brenner MK, Heslop HE, et al. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother. 2003;26:241-56. (Pubitemid 36686893)
23. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, et al. Use of gene-modifi ed virus-specifi c T lymphocytes to control Epstein - Barr-virus-related lymphoproliferation. Lancet. 1995;345:9-13.
24. Leen A, Ratnayake M, Foster A, Heym K, Ahmed N, Rooney CM, et al. Contact-activated monocytes: effi cient antigen presenting cells for the stimulation of antigen-specifi c T cells. J Immunother. 2007;30:96-107. (Pubitemid 46052208)
25. Kern F, Faulhaber N, Frommel C, Khatamzas E, Prosch S, Schonemann C, et al. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol. 2000;30:1676-82. (Pubitemid 30342810)
26. Leen AM, Christin A, Khalil M, Weiss H, Gee AP, Brenner MK, et al. Identifi cation of hexon-specifi c CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 2008; 82:546-54. (Pubitemid 350309169)
27. Chang ST, Ghosh D, Kirschner DE, Linderman JJ. Peptide length-based prediction of peptide-MHC class II binding. Bioinformatics. 2006;22:2761-7. (Pubitemid 44742396)
28. Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, et al. Functionally active virus-specifi c T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114:1958-67.
29. K umar D, Humar A. Cytomegalovirus prophylaxis: how long is enough? Nat Rev Nephrol. 2010;6:13-4.
30. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood. 1997;90:2502-8. (Pubitemid 27392736)
31. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063-71. (Pubitemid 26383133)
32. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, et al. Adoptive transfer of cytomegalovirusspecifi c CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202:379-86. (Pubitemid 41126955)
33. Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P, et al. Epstein - Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplantlymphoproliferative disease: prophylactic infusion of EBVspecifi c cytotoxic T cells. Blood. 2000;95:807-14. (Pubitemid 30062700)
34. Micklethwaite KP, Clancy L, Sandher U, Hansen AM, Blyth E, Antonenas V, et al. Prophylactic infusion of cytomegalovirusspecifi c cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modifi ed dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood. 2008;112:3974-81.
35. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffl er J, et al. Infusion of cytomegalovirus (CMV)-specifi c T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916-22. (Pubitemid 35332029)
36. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-44.
37. Cruz CR, Hanley PJ, Liu H, Torrano V, Lin YF, Arce JA, et al. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 2010;12:743-9.
38. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specifi c T-cellinfusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925-35.
39. Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, et al. An Epstein - Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specifi c CTLs. Blood. 2001;97:835-43. (Pubitemid 32154261)
40. + cytotoxic T cells from virus naive individuals. J Immunol. 2002;168: 909-18. (Pubitemid 34049595)
41. Waller EC, Day E, Sissons JG, Wills MR. Dynamics of T cell memory in human cytomegalovirus infection. Med Microbiol Immunol. 2008;197:83-96.
42. + and HLA-A2- donors. Biol Blood Marrow Transplant. 2004; 10:761-71. (Pubitemid 39409561)
43. + cytotoxic T-cell responses during chronic viral infection. J Virol. 1994;68:8056-63. (Pubitemid 24362694)